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Gap junctions (GJs) are hemichannels on cell membrane. Once they are intercellulary
connected to the neighboring cells, they build a functional syncytium which allows rapid
transfer of ions and molecules between cells. This characteristic makes GJs a potential
modulator in proliferation, migration, and development of the cells. So far, several types
of GJs are recognized on different brain cells as well as in glioma. Astrocytes, as one
of the major cells that maintain neuronal homeostasis, express different types of GJs
that let them communicate with neurons, oligodendrocytes, and endothelial cells of the
blood brain barrier; however, the main GJ in astrocytes is connexin 43. There are different
cerebral diseases in which astrocyte GJs might play a role. Several drugs have been
reported to modulate gap junctional communication in the brain which can consequently
have beneficial or detrimental effects on the course of treatment in certain diseases.
However, the exact cellular mechanism behind those pharmaceutical efficacies on GJs is
not well-understood. Accordingly, how specific drugs would affect GJs and what some
consequent specific brain diseases would be are the interests of the authors of this
chapter. We would focus on pharmaceutical effects on GJs on astrocytes in specific
diseases where GJs could possibly play a role including: (1) migraine and a novel therapy
for migraine with aura, (2) neuroautoimmune diseases and immunomodulatory drugs in
the treatment of demyelinating diseases of the central nervous system such as multiple
sclerosis, (3) glioma and antineoplastic and anti-inflammatory agents that are used in
treating brain tumors, and (4) epilepsy and anticonvulsants that are widely used for
seizures therapy. All of the above-mentioned therapeutic categories can possibly affect
GJs expression of astrocytes and the role is discussed in the upcoming chapter.
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INTRODUCTION
Gap junctions (GJs) are composed of 12 subunits of connexin
(Cx) in a way that each six connexins compose one connexon. The
opposing connexons on the neighboring cells form a GJ through
which small molecules up to 1 KD (secondmessengers, ATP, Ca2+
ions, etc.) can rapidly transfer in a network of connected cells.
GJs exist in almost all cell types except mature skeletal muscles,
spermatozoa, and erythrocytes (Dermietzel and Spray, 1993).
Although GJs possess some general features, they also exhibit
specific characteristics depending on the subtypes, cell types and
tissues. So far, 21 subtypes of Cxs have been found (Sohl and
Willecke, 2003). In the brain, neurons (Cx43, Cx32, Cx36), oligo-
dendrocytes (Cx32, Cx47, Cx29), astrocytes (Cx43, Cx30, Cx26),
and microglia (Cx43, Cx36, Cx32) express different Cxs (Rouach
et al., 2002; Nagy et al., 2004; Giaume and Theis, 2010); how-
ever, microglia expression of Cx43 is limited to specific brain
conditions such as injury or inflammation (Eugenin et al., 2001;
Giaume and Theis, 2010).
Besides the role as a channel, GJs may also exhibit hemichan-
nel activity, which is independent of their channel permeability
characteristics. Hemichannel activity of GJs refers to actions that
do not require the formation of a channel between opposing
connexons of the neighboring cells. It also means that their
opening state depends on specific conditions in the cell milieu and
according to available data and facilitates the transfer of glutha-
tion, prostaglandin E2, ATP and glutamate between extracellular
compartment and cytoplasm (Stout et al., 2002; Ye et al., 2003;
Bruzzone et al., 2005; Cherian et al., 2005; Saez et al., 2005; Rana
and Dringen, 2007).
On the other hand, hemichannel and channel activity can
be differentially regulated by certain stimulus. For example, the
inflammatory stimulus oppositely modulates the hemichannel
and channel activity of Cx43 on both astrocytes and C6 glioma
cell lines (De Vuyst et al., 2007; Retamal et al., 2007). C6 cells
showed reduction of Cx43 channel permeability under FGF-2
(fibroblast growth factor-2) and LPS (lipopolysaccharide) stimu-
lation; however, the hemichannel activity was increased. Likewise,
the treatment of astrocytes with the conditioned medium of
LPS-activated microglia, decreased dye coupling and gap junc-
tional communication (GJC) in astrocytes and enhanced the
hemichannel activity of Cx43 on astrocytes (Retamal et al., 2007).
Hemichannel features of GJs also have major roles in cytoskele-
tal organization and rapid normalization of toxic levels of Ca2+
as well as cell proliferation, migration, adhesion, and differ-
entiation during development. Finally, channel-dependent and
channel-independent features of GJs contribute to tumor cell
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adhesion, migration and proliferation just like glioma (Huang
et al., 1998; Lin et al., 2002, 2003; Bates et al., 2007; Cotrina et al.,
2008; Decrock et al., 2009; Crespin et al., 2010).
Microglia and astrocytes are major glial cells in the brain and
play important roles in maintaining homeostasis of neuronal
environment (Dermietzel et al., 1991). Astrocyte dysfunction
has been related to neuroautoimmune diseases, neoplasms and
epilepsy (Louis, 2006; Brinkmann, 2009; De Lanerolle et al.,
2010). The main focus of this chapter is astrocytes and their
function in therapeutic strategies in regard to GJs and dis-
eases. Authors will explore the effects of therapeutic agents on
astrocytes’ GJs in migraine, demyelinating disease of the central
nervous system (CNS), glioma and epilepsy.
DISCUSSION
MIGRAINE
Introduction
Migraine is recognized by repeated severe pulsating unilateral
headaches accompanied by photophobia, nausea and transient
neurological symptoms. Migraine with aura is a category in
which, headache is followed by visual disturbances. Several
hypotheses have been proposed for the development of migraine
with aura. A very old theory (vascular theory) proposed that the
rebound vasodilation following vasoconstriction of intracranial
arteries is the cause of perivascular sensory fibers and conse-
quently pain (Pietrobon and Striessnig, 2003). However, due to
lack of convincing evidence, this theory was argued and cur-
rently it is believed that some unknown molecular changes due
to cortical spreading depression (CSD) generation are the cause
of migraine. Neuronal excitements are thought to be the origin of
CSD, that is, the spreading of a cortical wave signal to the brain
cortex. CSD is believed to be the cause of several regional changes
in the extracellular fluid such as increasing the concentration of
K+ ions, nitric oxide, protons, and glutamate and thus vasodi-
lation of blood vessel in the brain. Consequently, perivascular
sensory fibers, branches of afferent trigeminal nerve, transfer the
data to the trigeminal nerve ganglia; and sensitization of sev-
eral pathways and nuclei in the brain stem causes pain (Olesen
et al., 1990; Bolay et al., 2002; Pietrobon and Striessnig, 2003;
Moskowitz, 2007; Silberstein, 2009).
Although the main cause of migraine initiation, according to
the CSD, seems to be neuronal activity, the data derived from
recent studies indicate an intimate role of satellite glial cells in the
trigeminal nerve as a major contributing and modulating factor.
Recently, it has been shown that astrocytes and their GJs might
contribute to the development of migraine (Silberstein, 2006;
Damodaram et al., 2009) and modulations of GJs can be help-
ful in migraine treatment. In this article, we are trying to address
the possible importance of GJs in the treatment of migraine.
Tonabersat and gap junctions
Because of the physiological characteristics of GJs, they could be
related as contributing factors for CSD theory. Astrocytes in the
close vicinity of synaptic cleft can receive “slip over” of neuro-
transmitters and respond by sending Ca2+ wave to connected
astrocytes via GJs or even send signals to remote astrocytes which
are not physically connected to them by GJs (Araque et al., 1999).
In either way, it was postulated that those astrocytes surround-
ing the ganglial neurons in trigeminal nerve have the potential to
take part in CSD activity andmigraine pathology (Thalakoti et al.,
2007). SB-220453 (Tonabersat), with a promising anti-epileptic
activity, was tested for this assumption in migraine and showed
a significant positive outcome in the treatment of migraine with
aura in rat and further in human (Chan et al., 1999; Damodaram
et al., 2009; Silberstein, 2009).
Tonabersat was first identified as an anti-epileptic drug (AED)
with specific but unknown binding sites in the brain that was
different from the commonly known AEDs. In addition, it had
no side effects on peripheral tissues such as heart, liver, and kid-
ney (Herdon et al., 1997; Upton et al., 1997). Due to its effect
on reducing plasma protein extravasation in rat trigeminal gan-
glion (Chan et al., 1999), it was studied as a potential candidate
for migraine headache therapy (Parsons et al., 2001). Tonabersat
affected Cx26 GJC between satellite glia cells and neurons in
the sensory part of the trigeminal nerve and prevented CSD
(Damodaram et al., 2009). Tonabersat reduced the neuroinflam-
mation and inhibited CSD, which could finally reduce migraine
attacks in animal models, as well as in human. Similarly, in an
in vivo experiment, Tonabersat reduced the elevated level of Cx26
in V1 and V2 regions which was previously increased by TNF-
α (an inflammatory cytokine) and capsaicin (Damodaram et al.,
2009). This finding implied a significant role for GJs of astrocytes
in the mechanism of action of Tonabersat in migraine therapy.
Beside the direct effect of Tonabersat on neuro-glia GJs, it
exhibited an indirect influence on GJs by activating microglia
in vitro. The microglia activation was a late response (>24 h)
followed by CSD induction and it was reversible (Gehrmann
et al., 1993); however, it could theoretically impose changes
on the GJs expression of astrocytes and consequently their
interaction with neurons and migraine. Although the functional
coupling between microglia and astrocytes through Cx43 has not
been confirmed, microglia modulates decrease the expression
and function of astrocytic Cx43 in vitro by releasing cytokines
(Faustmann et al., 2003; Retamal et al., 2007). As a result, we can
assume that a part of Tonabersat’s effect on neuro-glial GJs can
be mediated through an indirect effect on activation or increased
number or of regional microglia.
Conclusion
Tonabersat showed significant efficacy in the treatment of
migraine with aura. Although the mechanism of its effect is not
fully understood, the available data suggest a strong role for GJs
that are connecting neurons and satellite ganglion cells in trigem-
inal nerve. On the other hand, its indirect effect on microglia
activation can further influence the micro-milieu of neurons and
consequently their firing activity. However, whether GJC inhibi-
tion is the main pharmacological mechanism of Tonabersat in
human is the subject of further studies.
NEUROAUTOIMMUNE DISEASES
Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease of the
CNS which is characterized by degeneration of oligodendrocytes
and consequently demyelination of neurons (Compston and
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Coles, 2008). This further causes neuronal damage and axonal
loss and subsequent neurological deficits. Similarly, in neu-
romyelitis optica (NMO), a variant of MS, demyelination occurs
but with a different pathophysiology and localization. Although
the etiology of both diseases is unknown, NMO and MS are
categorized separately since 2006 (Wingerchuk et al., 2006).
Aquaporin4 (AQP4) is a water channel and is expressed on the
end-feet of astrocytes. Recent studies show that unlike MS, cir-
culating aberrant antibodies against AQP4 are highly raised in
the sera of patients with NMO (Lennon et al., 2004; Wingerchuk
et al., 2006).
Demyelination and gap junctions
The etiology of MS and NMO is associated with immune cells (T
and B cells), although the initiating cause is still unknown and
several contributing factors such as genetic predisposition, infec-
tions and vaccination, vitamin D deficiency, and environmental
factors have been suggested. Few studies have addressed the role
of GJs in neuroinflammatory diseases of MS or NMO (Ibrahim
et al., 2001; Brand-Schieber et al., 2005; Roscoe et al., 2007a,b).
Cx43 expression was evaluated in experimental autoimmune
encephalomyelitis (EAE) model of MS. For example, lumbar
spinal cord of EAE showed a significant reduction of astrocytic
Cx43, specifically in monocyte infiltrated areas (Brand-Schieber
et al., 2005). The reduction of Cx43 can be correlated to the local
release of some inflammatory properties of the lesion such as
the release of pro-inflammatory cytokine of interleukin-1 (IL-1)
(John et al., 1999). Interestingly, the reduction of Cx43 recov-
ers and even exceeds the normal baseline during remyelination
(Roscoe et al., 2007b). Due to lethal consequences of the deletion
of Cx43 in Knockout mice, Roscoe et al. could only study remyeli-
nation in Cx43 +/− (heterozygous null mutated) or Cx43 +/+
(wild type) mice. CT301 (α4-integrin blocker) or ADAC (adeno-
sine amine congener) improved clinical score and facilitated the
remyelination of EAE guinea pigs. Despite differences in Cx43
expression in these models, disease progression was similar in
both types (Roscoe et al., 2007a). On the contrary, the severity
of loss of Cx43 in human brain biopsies was associated with a
worse course of MS (Masaki et al., 2013). Therefore, the major
question of whether de/remyelination is caused by or is a cause of
Cx43 modulations, as Kielian suggested still remains unanswered
(Kielian, 2008).
A number of experiments on Cx Knockout mice (Cx43, Cx30,
Cx32, Cx47) showed massive demyelination in the EAE model
inferring the role for connexin in demyelinating diseases such as
MS (Menichella et al., 2003; Lutz et al., 2009; Magnotti et al.,
2011). Masaki et al. investigated Cx expression by immunohis-
tochemistry in 11 autopsied specimens of MS and NMO (Masaki
et al., 2013). They showed more intense Cx43 and Cx30 stain-
ing in normal gray matter than in white matter, especially at foot
process of astrocytes. In contrast, Cx30 level on astrocytes was
very low in NMO and MS lesions. Immunoreactivity to Cx43 was
completely lost in highly degenerative GFAP positive astrocytes
within the active lesion of MS or NMO. On the other hand, Cx43
was up-regulated in chronic lesions. The severity of loss of Cx43
was correlated with the clinical course of NMO and MS, that is,
extensive loss of Cx43 in the lesion was related to highly annual
relapse rate and rapid course of the disease. Interestingly, anti-
Cx43 antibody in the sera was negative in all samples (Masaki
et al., 2013). In general, the differential expression of Cx43 in
active and chronic lesion implies a distinguished role for Cx43
on different stages of inflammation in MS and NMO; however,
the related mechanism and how exactly Cx43 contributes in this
process are unknown yet.
FTY720 and gap junctions
MS has no cure but there are advanced therapies, including new
oral therapies, preventing the progression of the disease (Gold,
2011). They mostly modulate the immune system or the attach-
ment sites of immune cells to the endothelial layer of brain vessels.
FTY720 (Fingolimod) is a new oral treatment for MS and its
major function is to hold pathologic lymphocytes in the sec-
ondary lymphoid tissue in order to delay their release to the blood
stream and impede further brain damage (Matloubian et al.,
2004). FTY720 is a modulator of sphingosine 1-phosphate (S1P)
receptor with significant efficacy in the treatment of MS patients
(Brinkmann, 2009). Acting primarily on T cells, FTY720 down-
regulates S1P receptor 1 (S1P1), the receptor that T cells need
to express in order to escape the lymph node (Matloubian et al.,
2004).
Likewise, inflammation down-regulates S1P1 and entraps T
cells in the lymph node to optimize immune response in the body
(Schwab and Cyster, 2007). Sphingomyelin (part of the cell mem-
brane) degradation is the source of S1P in the body. Although all
cells can produce it, platelets and erythrocytes are the major sup-
pliers in plasma (Sano et al., 2002; Pappu et al., 2007). S1P plasma
level is usually low but it will rise during inflammation which
can impact various cells in which S1P receptors are expressed.
Other than lymphocytes, astrocytes express S1P receptors (S1P1,
S1P3) as well as oligodendrocytes and microglia/macrophages.
Accordingly, S1P could play a role in astrogliosis and neurode-
generative diseases (Waeber and Chiu, 1999; Sorensen et al., 2003;
Anelli et al., 2005; Jaillard et al., 2005; Kimura et al., 2007).
Inflammation, S1P, and gap junctions
GJ’s functions are modulated by several factors including neuro-
transmitters and proteins. Interestingly, Rouach and colleagues
evaluated the S1P effect on the GJC of astrocytes. They found
that S1P has a potent inhibitory effect on GJC and electrical
coupling of Cx43 of astrocytes by increasing dephosphorylated
Cx43 (Rouach et al., 2006). Dephosphorylation of Cx43 protein
imposes structural changes on Cx43 that finally reduces func-
tional GJC between astrocytes. They also showed that there was
no correlation between inhibition of GJC and mitotic activity.
However, further in vivo studies were not performed to evaluate
Cx43 GJC inhibition of astrocytes by S1P. As the authors sug-
gested, S1P could have a potential role in reactive astrogliosis in
brain. Due to the inflammatory nature of MS pathogenesis and
possible raise of S1P either in serum or the surroundings of astro-
cytes, these findings implicate the role of S1P modulations of
GJs on astrocytes that in turn could have further impacts on MS
progression.
It is speculated that microglia, another important glia in
brain, do not couple through Cx43 with astrocyte or each other,
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except for special situations like traumatic tissue cases (Eugenin
et al., 2001). However, it can influence astrocyte coupling through
diverse indirect mechanisms such as cytokine release (Faustmann
et al., 2003; Hinkerohe et al., 2005; Retamal et al., 2007). For
instance, interferon-beta (IFNβ) restored the reduction of astro-
cytes’ GJC caused by pro-inflammatory cytokines (IFNγ, IL-1β,
and IL-6) in cultured astrocytes (Hinkerohe et al., 2005). In addi-
tion, Cx43 expression showed a strong negative correlation with
microglia phenotype. Taken together, we can conclude that IFNβ,
that is widely administered for MS patients (McCormack and
Scott, 2004), can contribute to neutralizing the inflammatory
environment of astrocytes and GJ expression and consequently
help MS treatment (Hinkerohe et al., 2005). However, the long
term efficacy of such a treatment in reducing disability of MS
patients has been doubted (Shirani et al., 2012).
Conclusion
Despite the lack of definite evidence for the role of GJs in
the pathology of MS or NMO, these findings could imply
the role of GJs as contributors or modifying factors during
MS therapy or pathogenesis. Whether Cx43 is the cause or
effect of certain inflammation like cytokine release in demyeli-
nation pathology is a subject to be investigated in further
studies.
GLIOMA
Introduction
Brain neoplasm is a rare condition (<2% frequency); however,
it is lethal with poor prognosis (<1 year survival rate) (Parkin,
2001; Parkin et al., 2001). So far, only palliative treatments like
surgery and chemo/radio therapy are available but none of them
can cure the disease (Sin et al., 2012). There are two common
theories proposed for the origin of glioma: (1) astrocytes trans-
formed to a malignant type and (2) cancer stem cells (Singh et al.,
2003; Louis, 2006; Vescovi et al., 2006). These theories are based
on either the similar morphology of astrocytes to tumor cells
or the migration pattern of neural crest cells and glioma cells
(Dirks, 2001). The idea behind cancer stem cell as an origin for
brain tumor arose from the identification of stem cells among
leukemic cells. These stem cells possess the ability of proliferation
and self-renewal that would make them sufficient and necessary
for tumor progression and maintenance. The same pattern has
been recognized in brain tumor where stem cells were isolated
from different types of brain neoplasms. These cells showed sim-
ilar phenotypes although they were collected from different types
of tumors (Singh et al., 2003).
Gap junctions and glioma gene therapy
Cx43 expression is very heterogeneous in glioma; however, most
of the studies indicate that it has an inverse association with
glioma grade and is less expressed in glioma than normal tis-
sue (Soroceanu et al., 2001; Pu et al., 2004). Therefore, attempts
have been made to take advantage of Cx43 modulations in the
treatment of glioma like gene therapy.
In gene therapy, the main purpose is to insert a gene into
tumor cells that finally makes them sensitive to special medica-
tions. Herpes simplex virus-thymidine kinase (HSV-TK) suicide
gene therapy has been used to treat glioma (Ram et al., 1997;
Nicholas et al., 2003; Immonen et al., 2004). In HSV-TK gene
therapy, ganciclovir (GCV) treatment will further kill the infected
cells. However, scientists encountered a special phenomenon in
thismodel which was then called “bystander effect.” It was noticed
that the neighboring cells that were not induced by HSV-TK
were also killed after ganciclovir therapy in animal experimen-
tal models and total cell deaths outnumbered the transfected cells
(Moolten and Wells, 1990; Culver et al., 1992; Nicholas et al.,
2003).
Several hypotheses were raised to explain the bystander
effect: (1) non-infected cells died because of phagocytosing toxic
metabolites of dead cells, (2) the immune system became acti-
vated against tumor cells, (3) certain toxic metabolites were
transferred through cell-cell communication. Further studies sug-
gested the last theory as a better explanation for this effect.
For example, as the phosphorylated form of ganciclovir (GCV-
P) cannot cross cell membrane, the presence of GCV-P in the
neighboring non transfected cells was argued to be mediated by
GJs (Nicholas et al., 2003). Similarly, tumor cell lines, unable to
transfer calcein dye, did not show the bystander effect, either.
Calcein is a dye that only passes through GJs and the inhibition
of its transfer to neighboring cells infers to the inhibition of GJC.
Furthermore, increasing GJC led to more bystander cell death
such as the influence seen from apigenin or lovastatin in murine
adenocarcinoma cells (Touraine et al., 1998a,b).
Similar effects were observed in C6 cells. Normally, C6 cells
show less GJC (Naus et al., 1991); however, once they are trans-
fected with Cx43, they show higher GJC and bystander cell death
(Dilber et al., 1997; Robe et al., 2000). Surprisingly, in gene
therapy studies, the efficacy of bystander cell death was mostly
dependent on the Cx43 expression of the non TK-transduced
cells rather than the infected cells (Nicholas et al., 2003), a
phenomenon which emphasizes that higher GJC enhances the
bystander effect.
Besides Cx43, the role of other Cxs was investigated in glioma
gene therapy. Three different Cxs (Cx26, Cx32, Cx43) and their
effects on C6 glioma cell line proliferation and HSV-TK gene
therapy were further studied (Jimenez et al., 2006). Cx26 and
Cx32 had the most potent role in the efficient bystander effect of
HSV-TK therapy and Cx43 significantly contributed to this effect.
Modulation of Cxs was not directly evaluated at protein level;
however, the findings indirectly demonstrated the contribution of
Cx43 to glioma cell proliferation through measuring cell survival
after ganciclovir treatment (Jimenez et al., 2006). In conclusion,
these findings imply that for a better clinical approach, the higher
the expression of Cx43 in glioma cells is, the better the prognosis
for HSV-TK treatment would be.
Along with the role of Cx43 as a channel in glioma, studies
show that Cx43 can act as a tumor suppressor gene, as well (Zhu
et al., 1992; Goodenough et al., 1996; Omori and Yamasaki, 1998;
Huang et al., 1999; Zhang et al., 2003a). Investigating C6 cells
transfected with Cx43, Zhang et al. showed that Cx43 elevated p27
(cyclin-dependent kinase inhibitor) (Zhang et al., 2001, 2003b).
They also showed the decreased level of proto-oncogene SKP2
(S phase kinase-associated protein) which is probably the main
cause of P27 reduction in C6 cells. The authors could also clearly
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demonstrate that these effects were mediated by C-terminal of
Cx43, independent of channel permeability of Cx43. Therefore,
Cx43, as a hemichannel, could inhibit cell growth and applying
this hypothesis in the glioma therapy could prove beneficial.
Adjuvant chemo/radio therapies, Cx43 and glioma
To achieve increased Cx43 and consequently bystander
effect, adjuvant chemo/radio therapies have been studied.
Dexamethasone (DEX) is commonly used as a symptomatic
therapy for glioma patients to reduce edema and inflammation
(Kaal and Vecht, 2004). However, the administration of DEX is a
matter of debate because it can also be in favor of tumor growth
by reducing the sensitivity of tumor cells to common palliative
therapies like chemo/radiotherapy (Weller et al., 1997; Gorman
et al., 2000; Das et al., 2004).
Hinkerohe et al. investigated the role of DEX on functional
coupling and Cx43 expression of three different glioma cell lines.
They found that DEX decreases both functional GJC and Cx43
protein expression in all three cell lines (Hinkerohe et al., 2011).
They also used a co-culture model of astrocyte-microglia which
had a different yield in microglia numbers and demonstrated that
microglia play an important role in Cx43 expression of astro-
cytes (Figure 1) (Faustmann et al., 2003). In their in vitro model
DEX had no effect on astrocyte-microglia cultures containing
a low number of microglia (M5) in respect to functional cou-
pling, membrane resting potential (MRP), Cx43 expression and
microglia morphology. On the contrary, in cultures with a high
number of microglia (M30), DEX increased Cx43 expression
and GJC and decreased microglia activity based on morphology
assessment. Hinkerohe et al. claimed that this pattern is an in vitro
mimic of glioma in the brain, where M5 condition is representing
a healthy tissue and M30 stands for pathologic conditions located
in the close vicinity of glioma mass.
Similarly, the application of DEX in in vitro cultures of three
different cell lines reduced the bystander effect of HSV-TK gene
therapy, as well as GJC and sensitivity of tranfected cells to gan-
ciclovir (Robe et al., 2005). Although the in vitro results should
be carefully interpreted to be applied in vivo, they infer the point
that DEX administration in glioma could have a negative impact
on glioma treatment and should be handled cautiously.
Anti-epileptics, gap junctions, and glioma
Beside cytotoxic medication, patients commonly receive symp-
tomatic therapies in cancer. AEDs are used to treat seizures, one of
the most common complications in brain tumors (Van Breemen
et al., 2007). In conjunction with their role in controlling seizure,
they were also proposed to have a role in reducing tumor growth.
Sodium valproate (VPA) is commonly used as AED but it
has another function as a histone deacetylase inhibitor (HDAC).
HDACs have anti-cancer effects and can also modulate GJs in
glioma cell lines (Ammerpohl et al., 2004; Asklund et al., 2004;
Shao et al., 2004; Kuendgen and Gattermann, 2007; Duenas-
Gonzalez et al., 2008). On the other hand, glioma cells express
Cx26 in lower amounts, as well (Estin et al., 1999). Ryu et al.
investigated VPA’s role in HSV-TK gene therapy in U87 human
glioma cells and showed that the expression of Cx43 and Cx26
was increased by VPA treatment (Ryu et al., 2012).
FIGURE 1 | Immunocytochemical labeling of Cx43 expression (A,C) and
ED-1 positive cells (B,D) of astroglia/microglia co-cultures. (A,B)
Astrocytes co-cultured with about 5% microglial cells in order to mimic
physiological brain tissue. (C,D) Astrocytes co-cultured with about 30%
microglial cells in order to mimic inflammatory affected brain tissue. Glial
cells were counterstained with DAPI to visualize the nuclei (blue). (A)
Astroglial Cx43 Expression (green) under physiological mimicked in vitro
condition. (B) Microglia (red) are mostly found as inactivated, resting
ramified type under physiological condition. (C) Astroglial Cx43 Expression
(green) under inflammatory mimicked in vitro condition. The Cx43 protein
level is reduced in those cultures. (D) Microglia (red) proliferate and change
their phenotype to a round activated form under inflammatory condition.
This process could also be observed under in vitro conditions in cultures.
63x Magnification.
However, according to the meta-analysis study by Sirven et al.,
none of the three evaluated AEDs (phenobarbital, phenytoin,
VPA) could indicate beneficial effects as seizure prophylaxis in
glioma (Sirven et al., 2004) nor a correlation between VPA use
and survival rate was reported (Van Breemen et al., 2009). On the
contrary, in another study, AEDs, especially VPA, increased sur-
vival rates in glioma patients (Guthrie and Eljamel, 2013). The
controversy in these findings could raise the question of whether
the intrinsic characteristics (e.g., GJs expression) of tumor cells or
the stage of tumor are responsible for the diversity of the reaction
of AEDs in glioma treatment. In general, the remarkable aspect of
VPA as being anti-cancer agent (HDAC) and AED (GJs modula-
tions) makes it an interesting medication to investigate in glioma
treatment.
Homocellular and heterocellular gap junctional coupling
All mentioned studies evaluated the role of GJs in homocellu-
lar population; nevertheless, we should also consider the role
of heterojunctional coupling between astrocyte and glioma cells
(Oliveira et al., 2005) in pharmacological studies. Both glioma
and astrocytes express similar Cxs which hypothetically allow
them to connect through membranes and transfer metabolites
and certain molecules. The transfer of such molecules or metabo-
lites can be either detrimental or beneficial to cell proliferations of
both tumor cells and astrocytes. In addition, the other elements
residing in the brain tissue can modulate other factors such as
the blood flow of brain tissue. These changes can dramatically
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affect tumor growth and their micro-milieu. For example, during
or after ischemia, the glucose metabolism can oppositely modu-
late the effect of GJs on neuronal survival (Farahani et al., 2005).
These modifications can differentially affect GJC in astrocytes,
tumor cells or the combination of both.
Conclusion
With respect to GJs, there is evidence that less integrity within
glioma cell population and more integrity with the surround-
ing astrocytes would contribute to the migration of glioma cells
(Sin et al., 2012). Therefore, it is important to find a GJ selective
drug that is differentially affecting tumor cells and astrocytes. This
means GJs modulator should act in favor of astrocyte survival and
tumor cell eradication. Thus, far, Cx43 modulation did not show
a clear advantage in glioma treatment. However, further exper-
iments would clarify and probably introduce new treatments in
the future. Lastly, studies on the role of anti-inflammatory, anti-
cancer and AEDs on the co-cultures of astrocyte-glioma cells
could provide more information on the therapeutic role of GJs
in glioma.
EPILEPSY
Introduction
Epilepsy is one of the most common neurological disorders
affecting about 1% of the world population. According to the
definition of International League Against Epilepsy (ILAE) and
International Bureau of Epilepsy (IBE), epilepsy is a disorder
of the brain accompanied by neurologic, cognitive, psychologi-
cal, and social consequences of continued predisposition in the
brain that causes epileptic seizures (Fisher et al., 2005). Epilepsy
can have various reasons: traumatic brain injury, genetic predis-
position, stroke, or post-inflammatory responses in CNS. The
main focus of therapeutics is on reducing uncontrollable neu-
ronal firing in patients. Although neurons are thought to be
the main cause of epilepsy, glial cells gradually receive more
attention because of their direct interaction with neurons termed
as neuronal-glial network. In this network, glial cells take part in
the modulation of synaptic transmission through modifications
in channels, transporters, and receptors as well as GJs (Binder and
Steinhauser, 2006; Steinhauser et al., 2012; Binder and Carson,
2013). In the following, the influence of AEDs on GJs and their
potential role on epilepsy will be discussed.
Anti-inflammatory drug and gap junctions
The blockade of GJs has been referred to reduced seizure activ-
ity in animal models. Investigating the anticonvulsant poten-
tial of GJ blockade, Nilsen et al. (2006) and Jin et al. (2013)
applied meclofenamic acid (MFA) in epileptic rodent models.
They showed that MFA reduces seizure by blocking neuronal
Cx36 as well as astrocytic Cx43. The mechanism by which MFA
caused this effect is unknown; however, the anti-inflammatory
and strong GJs blockade properties of MFA could both play
a role. MFA belongs to non-steroidal anti-inflammatory drugs
(NSAID) family that inhibits cyclooxygenase (COX) pathways of
phospholipid degradation. The final results of COX activation
is prostaglandin (PG) synthesis and consequently, inflammation.
Therefore, MFA, as NSAID, can affect the micro-milieu in which
neurons, astrocytes and microglia reside and reduce the inflam-
mation caused by phospholipid degradation. On the other hand,
although GJs’ functional activity is reduced by inflammation,
MFA, as an anti-inflammatory drug, reduced GJC on astrocytes,
as well. Whether MFA has direct or indirect (via COX inhibi-
tion, PG synthesis, and micro-milieu modification) effects on GJs
activity in seizure will remain a question to be explored by fur-
ther studies. Nevertheless, these results support the assumption
of the proposed role of GJs in the seizures’ generation and propa-
gation. Considering the inflammatory theory for seizure (Vezzani
and Granata, 2005; Vezzani et al., 2011, 2013), the role of anti-
inflammatory cascades caused by anti-inflammatory drugs onGJs
and epilepsy is worth to investigate.
Table 1 | Summary of the available information in regard to GJs and brain pathologies in in vitro studies.
Disorder Drug Connexin Tissue Cell type Effect References
Migraine with aura SB-220453 (Tonabersat) Cx26 Trigeminal
Nerve
Satellite ganglial
cell, neuron
↓expression of Cx26
↓CSD
↓migraine attacks
Damodaram et al., 2009
Multiple sclerosis FTY720 (Fingolimod) Cx43 Brain Astrocyte ↓of GJC
↑dephosphorylated Cx43
Rouach et al., 2006
Multiple sclerosis IFNβ (Interferon-β) Cx43 Brain Astrocyte Restored astrocyte
depolarization restored
↓GJC
Hinkerohe et al., 2005
Glioma Dexamethasone CX43 Brain Glioma cell line ↓GJC
↓Cx43 expression
Hinkerohe et al., 2011
Glioma Sodium valproate Cx43,Cx26 Brain Glioma cell line ↑Cx43,Cx26 expression Ryu et al., 2012
Brain inflammation Dexamethasone Cx43 Brain Astrocyte ↑GJC
↑Cx43 expression
Hinkerohe et al., 2005
Epilepsy AEDs (Phenytoin,
Gabapentin, Sodium
valproate, Carbamazepine,
Levetiracetam)
Cx43 Brain Astrocyte ↑GJC and ↑Cx43
expression by
Levetiracetam, no
change on others
Haghikia et al., 2008;
Dambach et al., 2014
Cx, connexin; GJC, gap junctional communication; CSD, cortical spreading depression.
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Gap junctional blockade and epilepsy
Introducing GJs as possible interacting partners with neurons
in synapses (Araque et al., 1999), the impression of reducing
neuronal firing in epilepsy by manipulating GJs were examined.
Therefore, Carbenoxolone (CBX) as a non-selective GJ blocker
that exerts anti-epileptic effect in animal models was studied
(Gigout et al., 2006). The CBX effect on neurons decreases the
cumulative duration of cortical spike-wave discharges in an adult
rat genetic model of absence epilepsy. CBX also diminished
seizure-like primary after discharges in the rat CA1 hippocampal
pyramidal region and increased neuronal excitability in whole-
cell recordings (Jahromi et al., 2002). Beside neurons, CBX can
also affect astrocytes. Volume-regulated anion channels (VRAC)
are activated by hypotonic challenges in cultured rat cortical
astrocytes and low concentrations of CBX could inhibit this effect.
However, the same effect of CXB was observed in Cx43 Knockout
astrocytes (Benfenati et al., 2009). These results could imply the
point that CBX effect in epilepsy is probably mediated through
mechanisms other than Cx43 inhibition. Nevertheless, contro-
versial findings from other experimental studies require more
delicate methods and interpretation of the effect of GJ blockade
and epilepsy.
Anti-epileptic drugs and gap junctions
The effect of some common AEDs including phenytoin (PHE),
carbamazepine (CBZ), gabapentin (GBT), and VPA on the
astroglial Cx43 expression in astroglia/microglia cultures of new-
born rats was recently investigated (Dambach et al., 2014). In this
study, astrocytes were co-cultured with different percentages of
microglial cells (M5 or M30). Incubation with different concen-
trations of these AEDs, based on the levels of AEDs in liquor of
the patients, did not influence astroglial Cx43 expression. This
study could not provide an obvious role for AEDs with regard
to GJs modulation. The number of experiments and the nature of
the study of being in vitro could mask the possible effect in this
context.
However, in the study of Haghikia et al. levetiracetam (LEV)
increased Cx43 expression and GJC in astrocytes and restored
impaired astrocyte MRP via modification of inward and out-
ward rectifier currents in cultures with higher counts of microglia
(Haghikia et al., 2008; Stienen et al., 2011). The transfer of a
fluorescent dye from injected cells to the surrounding ones, was
considered as an indicator of GJC (in this experiment Cx43) activ-
ity. Participation of astrocytes in neural synapses as excitable cells
has not been completely confirmed. Nevertheless, due to the con-
nection of astrocytes and neurons via GJs, LEV can be a potential
modulator of neuronal excitability, as well.
Conclusion
Recent studies showed a role for inflammation and anti-
inflammatory drugs in epilepsy. Besides, microglia as a prominent
functional cell in inflammation has gained especial attention in
epilepsy. Likewise, modification of astrocytic Cx43 by microglia
has been investigated by several groups. Based on these findings,
manipulation of microglia to reduce inflammation would be ben-
eficial in epilepsy treatment. For example, a decrease in GJ perme-
ability can oppositely affect neuronal excitability by reflecting two
aspects: (1) a fast, pro-convulsive effect due to impaired K+ redis-
tribution, (2) delayed anti-epileptic effect because of disruption
of neuronal energy supply, which is mediated through astrocytes
(Seifert et al., 2006, 2010). Whether the final goal should be
reducing or increasing Cx43 is still an open question. However,
modulation of GJs in epilepsy remains a potential tool in epilepsy
treatment.
OUTLOOK
In conclusion, the in vitro pharmacological studies on astrocytic
GJs are sparse but have potential promising outcome for the treat-
ment of different brain diseases, especially glioma and epilepsy.
Table 1 summarizes the current information on the drug effects
and clinical applications of GJs in brain illnesses. Although GJ
manipulations do not function as a sole factor in treatment of
brain diseases, it can serve as a predicting factor in the progno-
sis of specific therapeutics as well as a contributing factor in the
etiology of certain CNS illnesses. Further studies on this topic
are warranted to signify GJs modulations under pharmacological
treatment.
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